Opens in a new tab

Edwards Lifesciences v Meril Life Sciences (CFI, 21 January 2025)

Date21 January 2025
CourtCFI
DivisionNordic Baltic Regional Division
Type of actionApplication RoP262.1 (b)
Registry referenceApp_33375/2024 · ORD_42124/2024
PartiesKIPA AB

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 21 January 2025 (UPC_CFI_380/2023, EP 3 769 722), the judge-rapporteur of the Nordic-Baltic Regional Division (Judge Johansson) closed, following their withdrawal, seven public access applications concerning the file in Edwards Lifesciences’ infringement action against Meril Life Sciences and others, and dismissed Meril Life Sciences’ request that the access applicant, whose name does not appear in the published version, reimburse EUR 17,168.70 in legal fees. The order rules out a costs order against a member of the public in Rule 262.1(b) proceedings.

Question

May a member of the public who withdraws an application for access to the file be ordered to reimburse the costs incurred by the parties consulted under Rule 262.1(b)?

Decision

The withdrawal, which also covered the request to add a co-applicant, led to closure. On costs, Art. 69(1) UPCA, based on Directive 2004/48, is not meant to apply to public access requests: no ceiling for recoverable costs has been set for them, and it is not for the judge-rapporteur to set their value (Rule 152.3). Rule 262.1(b) merely provides for consulting the parties to the main proceedings, who do not become parties to the access proceedings. Even if Rule 265 applied, its reference to costs is only a reminder. Neither the Court of Appeal’s order in UPC_CoA_404/2023, which made no costs order, nor the order of 18 September 2024 (UPC_CFI_8/2023), which gives no legal basis, provides one. Leave to appeal was granted.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 69(1) and Art. 73(2)(b)
Rules of Procedure
Rules 152.3, 156, 220.2, 224.1(b), 262.1(b), 262.2 and 265
Directive 2004/48/EC
Art. 14
Case law cited
Ocado Innovation, Court of Appeal, 8 February 2024, Nordic-Baltic Regional Division, 18 September 2024 (UPC_CFI_8/2023)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
Le juge rapporteur clôt les demandes d'accès retirées et rejette la demande de Meril Life Sciences tendant au remboursement de ses frais par le demandeur à l'accès, faute de base légale. L'appel est autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 769 722
Low profile delivery system for transcatheter heart valve
recorded proprietor: Edwards Lifesciences Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 9 other decision(s): Edwards Lifesciences v Meril Life Sciences (CFI, 21 July 2025) · Edwards Lifesciences v Meril Life Sciences (CFI, 12 May 2026) · EDWARDS LIFESCIENCES v MERIL LIFE SCIENCES (CFI, 5 December 2025) · Edwards Lifesciences v Meril Life Sciences (CFI, 2 September 2025) · Meril Life Sciences v Edwards Lifesciences (CFI, 11 December 2024) · EDWARDS LIFESCIENCES v MERIL LIFE SCIENCES (CFI, 10 December 2024) · Meril Life Sciences v Edwards Lifesciences (CoA, 21 November 2024) · Edwards Lifesciences v Meril Life Sciences (CFI, ORD_14940/2024, 20 Au
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.